Double-digit revenue increases in all its business segments propelled proton therapy developer Ion Beam Applications (IBA) to higher financial ground in the company's first quarter.
For the quarter (end-March 31), total revenues increased 13% to 73.3 million euros ($79.9 million U.S.), with sales of proton therapy and accelerators contributing a 12% gain and 58.7 million euros ($64 million). The company's dosimetry business segment advanced 19% in the first quarter to 14.6 million euros ($15.9 million).
The company also revised its forecast to 10% to 12% revenue growth for 2017 and 13% revenue growth for 2018.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
